We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market in 2025 or 2026 for hereditary angioedema, vasomotor symptoms, and glycogen storage disease.
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- A summary of epinephrine products for anaphylaxis.
- A spotlight on treatment landscapes and pipelines for immunoglobulin A (IgA) nephropathy, hypertrophic cardiomyopathy, and amyloidosis.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
